Early Research Suggests that Understanding the Fundamental Mechanism of Angiogenesis is More Complicated Than Understanding the Function of VEGF - A
Amgen Launches Angiogenesis Website
THOUSAND OAKS, Calif., April 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that results from several preclinical studies investigating potential new cancer agents will be presented at the 2009 American Association for Cancer Research (AACR) Annual Meeting in Denver between April 18-22, 2009.
Data will be presented on investigational compounds AMG 386, a peptibody that binds to and inhibits angiopoietins 1 and 2; AMG 479, a fully human monoclonal antibody antagonist of the type 1 insulin-like growth factor receptor (IGF-1R) and AMG 102, a fully human monoclonal antibody antagonist of HGF, the ligand for the c-Met receptor.
"The data being presented at this meeting further our biologic understanding of these novel compounds and pathways, and inform our thinking regarding opportunities to develop predictive or prognostic biomarkers," said C. Glenn Begley, M.D., vice president, Global Hematology and Oncology Research at Amgen. "This is an exciting year for our oncology therapeutics pipeline, as results from a number of clinical programs become available."
Selected Abstracts of Interest -- Assessment of angiogenesis inhibitors in the retinopathy of prematurity model in mice Overview: Examined the inhibition of the VEGF/VEGFR pathway with AMG 273 and the inhibition of the angiopoietin/Tie2 pathway with AMG 386 Lead author: Estrada J. Abstract No. 140 (Sunday, April 19, 2009, 8:00 am - 12:00 pm) -- Involvement of the CSF-1/CSF-1R interaction in the control of angiogenesis Overview: Two different neutralizin
Copyright©2009 PR Newswire.
All rights reserved